Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Zenas BioPharma, Inc.

NASDAQ: ZBIO · Life Sciences · 4 alerts · CIK 1953926

Share price
$27.93Close, Nov 16
Market cap
$1.89B
Shares outstanding
67.82MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Zenas BioPharma, Inc. filings on SEC EDGAR ↗

7:20 AM ET 10-Q
Financial Results

Zenas BioPharma Q3 2026 Results: Net Loss of $109M, Loss Widens

Zenas BioPharma, Inc. reported a significant increase in liquidity as of September 30, 2026, with cash, cash equivalents, and short-term investments totaling approximately $585.3 million, up from $343.2 million at the end of 2025. The company continues to operate as a non-accelerated filer and emerging growth company, focusing on the development of product candidates for immunology and inflammation diseases.

Key figure
Net loss $109M
7:13 AM ET 8-K
Financial Results

Zenas BioPharma Financial Results

Zenas BioPharma reported third quarter 2026 financial results and provided a corporate update, highlighting the FDA's acceptance of its BLA for obexelimab with a PDUFA date of May 27, 2027. The company ended the quarter with $647.1 million in cash and investments, which it expects will fund operations into 2027 as it prepares for potential commercialization.

Term
Q3 2026

“This quarter we continued to execute across our portfolio as we prepare for the potential commercialization of obexelimab for the treatment of IgG4-RD. Following the FDA’s acceptance of our BLA in the second quarter of this year, and the recent submission of our MAA to the EMA, we remain focused on commercial readiness ahead of the potential launch.”

Lonnie Moulder, Founder and Chief Executive Officer

“Across our broader pipeline, we remain on track to report topline Phase 2 SunStone data in SLE and initial Phase 1 data for our oral IL-17 inhibitor, ZB021, this quarter. We look forward to closing out a very productive year as we turn our attention to 2027 and continue to build toward our vision of becoming a fully integrated, global development and commercial-stage biopharmaceutical company.”

Lonnie Moulder, Founder and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.